Drug
AZD9550 clinical trials
Also written AZD9550.
- studies test it
- 6
- open now
- 1
- in phase 3
- 0
- first study started
- 2023
Keep track of what changes. Save the AZD9550 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses AZD9550 is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234RecruitingPhase 1AstraZenecaNCT07546760Written as AZD9550
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightActive, not recruitingPhase 1/2AstraZenecaNCT06151964Written as AZD9550
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or ObesityActive, not recruitingPhase 1AstraZenecaNCT07013643Written as AZD9550
- This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightActive, not recruitingPhase 2AstraZenecaNCT07017179Written as AZD9550
- A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneCompletedPhase 2AstraZenecaNCT06862791Written as AZD9550
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy ParticipantsCompletedPhase 1AstraZenecaNCT05848440Written as AZD9550